These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 10815784

  • 1. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.
    Am J Hematol; 2000 May; 64(1):26-31. PubMed ID: 10815784
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 5. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE.
    N Engl J Med; 2020 Jun 25; 382(26):2524-2533. PubMed ID: 32579813
    [Abstract] [Full Text] [Related]

  • 6. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home.
    Ballas SK, Bauserman RL, McCarthy WF, Castro OL, Smith WR, Waclawiw MA, Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    J Pain Symptom Manage; 2010 Dec 25; 40(6):870-82. PubMed ID: 20864308
    [Abstract] [Full Text] [Related]

  • 7. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR.
    N Engl J Med; 1995 May 18; 332(20):1317-22. PubMed ID: 7715639
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
    Costa E, Tibalinda P, Sterzi E, Leufkens HMG, Makani J, Kaale E, Luzzatto L.
    Am J Hematol; 2021 Jan 18; 96(1):E2-E5. PubMed ID: 32974896
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP, Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    N Engl J Med; 2018 Jul 19; 379(3):226-235. PubMed ID: 30021096
    [Abstract] [Full Text] [Related]

  • 13. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
    Cunningham-Myrie C, Abdulkadri A, Waugh A, Bortolusso Ali S, King LG, Knight-Madden J, Reid M.
    Pediatr Blood Cancer; 2015 Oct 19; 62(10):1862-4. PubMed ID: 25929458
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea.
    Charache S, Terrin ML, Moore RD, Dover GJ, McMahon RP, Barton FB, Waclawiw M, Eckert SV.
    Control Clin Trials; 1995 Dec 19; 16(6):432-46. PubMed ID: 8925656
    [Abstract] [Full Text] [Related]

  • 16. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE, REACH Investigators.
    N Engl J Med; 2019 Jan 10; 380(2):121-131. PubMed ID: 30501550
    [Abstract] [Full Text] [Related]

  • 17. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.
    Blood; 1999 Sep 01; 94(5):1550-4. PubMed ID: 10477679
    [Abstract] [Full Text] [Related]

  • 18. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J, HOPE Trial Investigators.
    N Engl J Med; 2019 Aug 08; 381(6):509-519. PubMed ID: 31199090
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.